Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RAPT

RAPT Therapeutics Inc

Dec 27 • 03:44PM ET

1.80

Dollar change -0.01
Percentage change -0.55	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY NBIX EXEL BPMC FGEN APLS KURA BLUE MEIP

| Held by: IWM VTI VXF IWN VTWO CNCR VHT IWC DFAT ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.78	Insider Own	9.11%	Shs Outstand	34.90M	Perf Week	122.83%
Market Cap	62.92M	Forward P/E	-	EPS next Y	-0.85	Insider Trans	0.00%	Shs Float	31.77M	Perf Month	60.71%
Income	-107.49M	PEG	-	EPS next Q	-0.32	Inst Own	92.25%	Short Float	5.40%	Perf Quarter	-8.16%
Sales	0.00M	P/S	-	EPS this Y	30.16%	Inst Trans	-6.43%	Short Ratio	0.57	Perf Half Y	-40.98%
Book/sh	2.74	P/B	0.66	EPS next Y	60.14%	ROA	-69.76%	Short Interest	1.72M	Perf Year	-92.77%
Cash/sh	2.80	P/C	0.64	EPS next 5Y	-	ROE	-80.13%	52W Range	0.79 - 27.35	Perf YTD	-92.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.39%	ROI	-109.57%	52W High	-93.42%	Beta	0.03
Dividend TTM	-	Quick Ratio	9.90	Sales past 5Y	-36.87%	Gross Margin	-	52W Low	128.06%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	9.90	EPS Y/Y TTM	3.64%	Oper. Margin	-	RSI (14)	66.67	Volatility	22.90% 13.16%
Employees	131	Debt/Eq	0.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.60	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	42.06%	Payout	-	Rel Volume	1.01	Prev Close	1.81
Sales Surprise	-	EPS Surprise	18.92%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	3.03M	Price	1.80
SMA20	54.48%	SMA50	18.74%	SMA200	-49.86%	Trades		Volume	2,928,681	Change	-0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-26-24	Upgrade	H.C. Wainwright	Neutral → Buy	$10
Nov-13-24	Downgrade	Stifel	Buy → Hold	$7 → $2
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$8 → $2
Nov-11-24	Downgrade	JP Morgan	Neutral → Underweight
May-14-24	Downgrade	Wolfe Research	Outperform → Peer Perform
May-10-24	Downgrade	Guggenheim	Buy → Neutral
May-10-24	Downgrade	Barclays	Overweight → Equal Weight	$13 → $4
Feb-22-24	Downgrade	UBS	Buy → Neutral	$61 → $10
Feb-21-24	Downgrade	Leerink Partners	Outperform → Market Perform	$42 → $10
Feb-21-24	Downgrade	JP Morgan	Overweight → Neutral	$35 → $15
Feb-21-24	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-20-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-16-24	Initiated	Evercore ISI	Outperform
Feb-15-24	Initiated	Wolfe Research	Outperform	$39
Sep-14-23	Initiated	Berenberg	Buy	$34
Aug-09-23	Initiated	Stifel	Buy	$40
Jun-15-23	Initiated	Barclays	Overweight	$35
Jan-04-23	Initiated	Guggenheim	Buy	$55
Dec-01-22	Initiated	Goldman	Buy	$27
Sep-21-22	Initiated	CapitalOne	Overweight	$48

Show Previous Ratings

Today 06:10AM	Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright (TipRanks)
Dec-26-24 09:35AM	Progressive, EverQuote upgraded: Wall Street's top analyst calls (The Fly)
Dec-24-24 06:44AM	RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement (Pharmaceutical Technology)
Dec-23-24 01:00PM	Why RAPT Therapeutics Stock Gained Over 100% On Monday? (Benzinga) +110.81%
07:10AM	RAPT Therapeutics Announces $150 Million Private Placement (GlobeNewswire)
07:00AM	Loading…
07:00AM	RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody (GlobeNewswire)
Nov-12-24 08:00AM	RAPT Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-11-24 12:18PM	RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull (Clinical Trials Arena) -39.45%
08:00AM	Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury (GlobeNewswire)
Sep-29-24 07:57AM	RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:34AM	RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability (Insider Monkey)
Aug-08-24 08:00AM	RAPT Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-21-24 01:13AM	Should You Sell Your Stake in RAPT Therapeutics (RAPT)? (Insider Monkey)
Jun-14-24 09:35AM	Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround (Zacks)
May-29-24 09:35AM	Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
07:08AM	Loading…
May-14-24 07:08AM	Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform (MT Newswires) -9.09%
May-13-24 09:35AM	Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks (Zacks)
May-10-24 03:46PM	RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com) -7.08%
07:55AM	Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy (MT Newswires)
07:54AM	Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4 (MT Newswires)
May-09-24 04:12PM	What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday? (Benzinga) -41.60%
03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires)
02:31PM	RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials (MT Newswires)
01:53PM	RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	RAPT Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-09-24 12:00PM	RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients (GlobeNewswire)
06:31AM	3 Biotech Stocks to Dump Before They Go to Zero (InvestorPlace)
Mar-22-24 05:39AM	What Makes RAPT Therapeutics (RAPT) an Investment Choice? (Insider Monkey)
Mar-07-24 02:52PM	RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
08:36AM	Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? (Zacks)
08:00AM	Loading…
08:00AM	RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 04:30PM	RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +5.30%
Feb-20-24 04:03PM	Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests (Investor's Business Daily) -73.55% +48.18%
11:22AM	RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure. (Barrons.com)
07:58AM	UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials (Reuters)
07:39AM	RAPT Therapeutics says FDA puts two mid-stage trials of company's drug on hold (Reuters)
07:30AM	RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon (GlobeNewswire)
07:17AM	FDA puts hold on Rapt trials of drug for eczema, asthma (BioPharma Dive)
Feb-13-24 08:00AM	RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations (GlobeNewswire) -5.52%
Jan-31-24 08:00AM	RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-02-24 08:00AM	RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-27-23 08:00AM	RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy (GlobeNewswire)
Nov-14-23 07:41PM	RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials (GuruFocus.com) -5.28%
Nov-13-23 08:00AM	RAPT Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:00PM	RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC (GlobeNewswire) +9.08%
Nov-01-23 04:05PM	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November (GlobeNewswire) +8.21%
Oct-18-23 09:00AM	RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 09:44AM	Etsy upgraded, RTX downgraded to Sell: Wall Street's top analyst calls (The Fly)
Aug-30-23 04:05PM	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September (GlobeNewswire)
Aug-16-23 09:55AM	How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 90.48% (Zacks) -9.45%
Aug-11-23 08:00AM	RAPT Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly) +6.51%
Aug-08-23 06:03AM	This RAPT Therapeutics Insider Increased Their Holding By 22% Last Year (Simply Wall St.)
Jun-07-23 08:00AM	RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers (GlobeNewswire)
May-11-23 08:00AM	RAPT Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 08:00AM	RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel (GlobeNewswire) +6.89%
Apr-26-23 04:19PM	RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-29-23 08:00AM	RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma (GlobeNewswire)
Mar-21-23 08:50AM	Here's Why We're Not Too Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation (Simply Wall St.)
Mar-14-23 08:00AM	RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results (GlobeNewswire) -25.97%
Mar-02-23 10:00AM	Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-28-23 08:00AM	Factors to Note Ahead of Hewlett Packard (HPE) Q1 Earnings (Zacks)
Feb-27-23 09:55AM	Wall Street Analysts See a 57.57% Upside in Rapt Therapeutics (RAPT): Can the Stock Really Move This High? (Zacks)
Feb-23-23 08:50AM	What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing' (Zacks)
Feb-22-23 06:31AM	Great news for RAPT Therapeutics, Inc. (NASDAQ:RAPT): Insiders acquired stock in large numbers last year (Simply Wall St.)
Feb-16-23 04:02AM	Emergent Biosolutions (EBS) Moves 12.5% Higher: Will This Strength Last? (Zacks)
Feb-10-23 09:55AM	Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet (Zacks)
Feb-07-23 08:00AM	RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 05:43PM	2 Strong Buy Small Cap Stocks That Can Rip Higher in 2023 (TipRanks) +7.75%
Jan-25-23 08:50AM	Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT) (Zacks)
Jan-03-23 08:00AM	RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.01%
Dec-30-22 09:55AM	Does Rapt Therapeutics (RAPT) Have the Potential to Rally 122% as Wall Street Analysts Expect? (Zacks)
Dec-17-22 08:56AM	Investors in RAPT Therapeutics (NASDAQ:RAPT) have unfortunately lost 44% over the last year (Simply Wall St.)
Dec-08-22 06:30AM	RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer (GlobeNewswire)
Nov-30-22 07:05PM	RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress (GlobeNewswire)
Nov-22-22 08:46AM	Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick (Zacks)
Nov-17-22 09:38PM	RAPT Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.45%
04:24PM	RAPT Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:55AM	How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 116% (Zacks)
Nov-12-22 07:42AM	RAPT Therapeutics Third Quarter 2022 Earnings: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021) (Simply Wall St.)
Nov-10-22 09:15AM	Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +26.18%
08:00AM	RAPT Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-09-22 08:00AM	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences (GlobeNewswire) -5.68%
Oct-12-22 07:50AM	RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Sep-28-22 08:00AM	RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires (GlobeNewswire)
Sep-23-22 12:00PM	Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Here's Why Rapt Therapeutics (RAPT) Looks Ripe for Bottom Fishing (Zacks)
Sep-15-22 06:17AM	Quite a few insiders invested in RAPT Therapeutics, Inc. (NASDAQ:RAPT) last year which is positive news for shareholders (Simply Wall St.)
Sep-01-22 09:55AM	How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74% (Zacks)
Aug-31-22 08:00AM	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September (GlobeNewswire)
Aug-16-22 09:55AM	Can Rapt Therapeutics (RAPT) Climb 59% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-11-22 09:15AM	Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	RAPT Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-10-22 09:37AM	RAPT Therapeutics (NASDAQ:RAPT) adds US$74m to market cap in the past 7 days, though investors from a year ago are still down 39% (Simply Wall St.)
Jun-20-22 09:25AM	Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last? (Zacks)
May-25-22 03:01PM	This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So (Benzinga) +9.12%
08:00AM	RAPT Therapeutics Announces Private Placement Financing of $50 Million (GlobeNewswire)
May-23-22 08:00AM	RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -6.55%

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brockstedt Dirk G.	CHIEF SCIENTIFIC OFFICER	Jan 05 '24	Sale	22.78	898	20,456	27,820	Jan 08 05:50 PM
Brockstedt Dirk G.	Chief Scientific Officer	Dec 29 '23	Option Exercise	6.18	8,000	49,440	27,070	Jan 02 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPT

RAPT Therapeutics Inc

Upgrade your FINVIZ experience